2 terminated. 2 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 2 | Terminated 2 |
Follow PF-07284892: new trials by email Literature Review of PF-07284892 trials Research Report on PF-07284892
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Study to Learn About the Study Medicine PF-07985045 When Given Alone or With Other Anti-cancer Therapies in People With Advanced Solid Tumors That Have a Change in a Gene. PF-07985045, Gemcitabine, Nab-paclitaxel - Carcinoma, Pancreatic Ductal, Colorectal Neoplasms | Phase 1 | Terminated | Pfizer | 30 | 2024-12-10 | 2026-05-22 |
| PF-07284892 in Participants With Advanced Solid Tumors PF-07284892, lorlatinib, binimetinib - Solid Tumor | Phase 1 | Terminated | Pfizer | 53 | 2021-03-17 | 2026-06-04 |
Carcinoma, Non-Small-Cell Lung (2) · Colorectal Neoplasms (2) · Carcinoma, Pancreatic Ductal (1) · Colonic Neoplasms (1) · Hereditary Sensory and Autonomic Neuropathies (1) · Lung Neoplasms (1) · Neurofibromatosis 1 (1) · Rectal Neoplasms (1)
Pfizer (2)
United States (2) · Puerto Rico (1)